title: A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
authors: Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France.
authors: Maryline
authors: M
authors: Allegra
authors: Department of Dermatology, CHU Nice, Nice, France.
authors: Damien
authors: D
authors: Giacchero
authors: Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France.
authors: Coralie
authors: C
authors: Segalen
authors: INSERM U976, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors: Nicolas
authors: N
authors: Dumaz
authors: IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
authors: Catherine
authors: C
authors: Butori
authors: UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
authors: Véronique
authors: V
authors: Hofman
authors: UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; IRCAN Equipe 3, and Hospital-Integrated Tumor Biobank, INSERM U 1081, Nice, France.
authors: Paul
authors: P
authors: Hofman
authors: Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France.
authors: Jean-Philippe
authors: JP
authors: Lacour
authors: Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France.
authors: Corine
authors: C
authors: Bertolotto
authors: Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France; Clinical Research Centre, CHU Nice, Nice, France. Electronic address: bahadoran.p@chu-nice.fr.
authors: Philippe
authors: P
authors: Bahadoran
authors: Equipe Labellisée par la Ligue Contre le Cancer, Biology and Pathologies of Melanocytes, Equipe 1, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Nice, France; Department of Dermatology, CHU Nice, Nice, France; UFR Médecine, Université de Nice-Sophia Antipolis, Nice, France. Electronic address: ballotti@unice.fr.
authors: Robert
authors: R
authors: Ballotti
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D015398:Signal Transduction / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit